Waypoint Wealth Counsel’s AbbVie ABBV Stock Holding History

Waypoint Wealth Counsel’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Sell	1,460 -141	-9%	-$30.3K	0.23%	75
2026 Q1	$348K	Sell	1,601 -1,166	-42%	-$259K	0.18%	115
2025 Q4	$632K	Sell	2,767 -326	-11%	-$74.3K	0.23%	83
2025 Q3	$716K	Buy	3,093 +159	+5%	+$32.4K	0.28%	56
2025 Q2	$545K	Sell	2,934 -18	-0.6%	-$3.35K	0.27%	57
2025 Q1	$618K	Sell	2,952 -393	-12%	-$76.4K	0.39%	46
2024 Q4	$594K	Sell	3,345 -97	-3%	-$17.8K	0.39%	46
2024 Q3	$680K	Buy	3,442 +88	+3%	+$16.4K	0.46%	43
2024 Q2	$575K	Sell	3,354 -45	-1%	-$7.45K	0.44%	42
2024 Q1	$619K	Buy	3,399 +87	+3%	+$15K	0.48%	41
2023 Q4	$513K	Sell	3,312 -267	-7%	-$38.9K	0.44%	47
2023 Q3	$534K	Buy	3,579 +35	+1%	+$5.14K	0.5%	41
2023 Q2	$477K	Sell	3,544 -2,054	-37%	-$301K	0.43%	45
2023 Q1	$892K	Buy	5,598 +53	+1%	+$8.1K	0.69%	33
2022 Q4	$896K	Buy	+5,545	New	+$850K	0.72%	35

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Waypoint Wealth Counsel's ABBV Position: Q2 2026 in Review

Waypoint Wealth Counsel reduced its AbbVie (ABBV) stake by 8.8% in Q2 2026, selling an estimated $30.3K and leaving 1,460 shares worth $367K. The position accounts for 0.23% of the portfolio, ranked #75.

Waypoint Wealth Counsel first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $896K in Q4 2022. 4,216 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Waypoint Wealth Counsel held 1,460 shares of AbbVie worth $367K as of Q2 2026.
Waypoint Wealth Counsel sold 141 AbbVie shares in Q2 2026, an estimated $30.3K.
AbbVie made up 0.23% of Waypoint Wealth Counsel's portfolio in Q2 2026, its #75 holding.
Waypoint Wealth Counsel first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
Waypoint Wealth Counsel's AbbVie position peaked at $896K in Q4 2022.
4,216 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q2 2026, filed 4 Aug 2026.